Navigation Links
MeiraGTx Awarded Target ALS Grant For Its NMD-Based Therapy for ALS
Date:2/1/2017

NEW YORK, Feb. 1, 2017 /PRNewswire/ -- MeiraGTx, a New York and UK based gene therapy company, announced today that it has been awarded a grant from Target ALS, a privately funded foundation bringing together a consortia of academic and biotech/pharmaceutical researchers focused on finding treatments for ALS patients. Target ALS is jointly funding this grant with the research organization ALS Finding A Cure®.  The grant will fund testing of a novel gene therapy approach to treat this devastating neurodegenerative disease that targets TDP-43, a protein that is misregulated in over 95% of all ALS patients. The approach would control misregulated proteins in the cell. Out of 43 applicants for the industry-led consortium funding, MeiraGTx was one of just five awardees. The grant was reviewed by an independent review committee comprised of senior investigators in academia and in the biotech/pharmaceutical industry.

The ALS-associated protein TDP-43 has been emerging as a possible Achilles' Heel in ALS treatment.  Research conducted by Dr. Greg Petsko and colleagues at Weill Cornell Medicine and Brandeis University has revealed that one of the cell's own quality control mechanisms, the nonsense-mediated decay (NMD) pathway, appears to be able to alleviate TDP-43 mediated toxicity in cell and animal based disease models of ALS. The research found that increased expression of UPF1, the master regulator of NMD, can significantly protect mammalian motor neurons from TDP-43 mediated toxicity.

The grant was received to confirm and extend initial findings on the efficacy of this therapeutic approach. MeriaGTx will test the approach in well-characterized mouse models of ALS derived in the laboratory of Dr. Neil Shneider at the Columbia College of Physicians and Surgeons, and through the use of biochemical methods defined in the Petsko and MeiraGTx lab will generate candidate biologics that are even more potent in generating the same response.

"Target ALS is pleased to support the MeiraGTx led collaborative consortium," said Manish Raisinghani, President of the Target ALS Foundation. "This award is part of our goal to seed and support ALS drug discovery programs in the pharma and biotech industries to realize new treatments for this devastating disease."

"Joining with Target ALS to increase the number of researchers developing novel treatments for ALS is a great opportunity to advance our ultimate mission to cure this deadly disease," said Peter Foss, President of ALS Finding A Cure®. "We are proud to be a part of this innovative effort."   

"We are honored to receive this prestigious grant to help us pursue our promising findings about NMD-based therapy," said Alexandria Forbes, Ph.D., President and CEO of MeiraGTx. "We believe this is a key development in the treatment of ALS and that our novel approach may help the thousands of people affected by this devastating neurodegenerative disease." 

About MeiraGTx 

MeiraGTx is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders.  The company is developing treatments for ocular diseases, including rare inherited blindness and age-related macular degeneration (AMD).  MeiraGTx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers, as well as certain neurodegenerative diseases.  In addition, MeiraGTx is developing novel gene regulation platforms that promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.

About Target ALS

Target ALS Foundation (www.targetals.org) is a non-profit organization with the overall goal of accelerating development of new treatments for ALS.  We drive emergence of novel ALS drug discovery programs in industry by funding collaborative consortia focused on development of novel therapeutic targets.  To ensure that all new ideas get tested, we make essential tools and resources openly available to all - especially young investigators - with no embargo or strings attached.

About ALS Finding A Cure

ALS Finding A Cure® is dedicated to being a game changer in discovering a cure for this fatal disease. Founded in 2014 by noted philanthropist and Conair Founder and Chairman, Leandro (Lee) Rizzuto, as a tribute to Christie Rizzuto, Lee's daughter-in-law who was diagnosed with ALS in 2009 at the age of 41, and under the leadership of Peter N. Foss and a team of reknowned ALS researchers, ALS Finding A Cure® is focused on identifying the gaps in the scientific understanding of ALS that are preventing the development of a cure. The organization, a program of The Leandro P. Rizzuto Foundation, collaborates with a wide range of companies, ALS organizations, other disease research organizations, and ALS patients and families to ensure research efforts are non-duplicative, synergistic, and focused on the ultimate goal: finding a cure. For more information about ALS Finding a Cure®, visit http://www.alsfindingacure.org.

Forward-Looking Statements

This press release contains forward-looking statements. These forward-looking statements are based on management's expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. MeiraGTx expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Contact:
Andy Merrill
Prosek Partners
212-279-3115, ext. 216

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/meiragtx-awarded-target-als-grant-for-its-nmd-based-therapy-for-als-300399906.html


'/>"/>
SOURCE MeiraGTx
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Personal Genome Diagnostics Awarded National Cancer Institute Contract to Develop Novel Diagnostic for Immuno-Oncology Drugs
2. This Years Crafoord Prize is Awarded for Fundamental Discoveries in Immune Regulation
3. CE Marking Awarded to Parkinsons Digital Health Technology
4. Kewaunee Scientific Awarded $8.4 Million Contract for CUNY Project
5. Bodycad Awarded Key US Patents for Improving Accuracy, Reproducibility and Speed for 3D Imaging in Orthopaedic Applications
6. Boehringer Ingelheim Awarded Perfect Score for Workplace Equality for the LGBT Community
7. Anuva Manufacturing Services Awarded ISO-13485:2003 Certification
8. Southern Research awarded $500,000 U.S. Department of Commerce grant to expand medical device innovation and commercialization
9. CytoSorbents Awarded $150,000 Phase I STTR Contract for Universal Plasma Development
10. Implantable Glucose Sensor Featuring IDT Sensing Technology Awarded CE Mark
11. Nationwide Pharmaceutical Awarded $495,000 Pharmacy Benefit Management Services Contract (aka First-Fill Pharmacy Services) VA256-16-D-0056
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, https://wcg.swoogo.com/modern-sop-and-quality-systems , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):